These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33396282)

  • 1. The Anticancer Peptide CIGB-552 Exerts Anti-Inflammatory and Anti-Angiogenic Effects through COMMD1.
    Daghero H; Fernández Massó JR; Astrada S; Guerra Vallespí M; Bollati-Fogolín M
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33396282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis reveals amino acids critical for anticancer activity of peptide CIGB-552.
    Astrada S; Gomez Y; Barrera E; Obal G; Pritsch O; Pantano S; Vallespí MG; Bollati-Fogolín M
    J Pept Sci; 2016 Nov; 22(11-12):711-722. PubMed ID: 27933724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models.
    Gomez Rodriguez Y; Oliva Arguelles B; Riera-Romo M; Fernandez-De-Cossio J; Garay HE; Fernandez Masso J; Guerra Vallespi M
    Mol Biol Rep; 2022 Apr; 49(4):3197-3212. PubMed ID: 35094208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Penetrating Capacity and Internalization Mechanisms Used by the Synthetic Peptide CIGB-552 and Its Relationship with Tumor Cell Line Sensitivity.
    Astrada S; Fernández Massó JR; Vallespí MG; Bollati-Fogolín M
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29601540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models.
    Vallespí MG; Pimentel G; Cabrales-Rico A; Garza J; Oliva B; Mendoza O; Gomez Y; Basaco T; Sánchez I; Calderón C; Rodriguez JC; Markelova MR; Fichtner I; Astrada S; Bollati-Fogolín M; Garay HE; Reyes O
    J Pept Sci; 2014 Nov; 20(11):850-9. PubMed ID: 25044757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
    Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG
    Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-class, first-in-human, phase I trial of CIGB-552, a synthetic peptide targeting COMMD1 to inhibit the oncogenic activity of NF-κB in patients with advanced solid tumors.
    Vallespi MG; Mestre B; Marrero MA; Uranga R; Rey D; Lugiollo M; Betancourt M; Silva K; Corrales D; Lamadrid Y; Rodriguez Y; Maceo A; Chaviano PP; Lemos G; Cabrales A; Freyre FM; Santana H; Garay HE; Oliva B; Fernandez JR
    Int J Cancer; 2021 Sep; 149(6):1313-1321. PubMed ID: 34019700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The first report of cases of pet dogs with naturally occurring cancer treated with the antitumor peptide CIGB-552.
    Vallespi MG; Rodriguez JC; Seoane LC; Alvarez P; Santana H; Garay H; Cabrera IA; Espinosa JT; Reyes O
    Res Vet Sci; 2017 Oct; 114():502-510. PubMed ID: 28987957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells.
    Fernández Massó JR; Oliva Argüelles B; Tejeda Y; Astrada S; Garay H; Reyes O; Delgado-Roche L; Bollati-Fogolín M; Vallespí MG
    J Amino Acids; 2013; 2013():251398. PubMed ID: 23401744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative proteomics analysis of the antitumor effect of CIGB-552 peptide in HT-29 colon adenocarcinoma cells.
    Núñez de Villavicencio-Díaz T; Ramos Gómez Y; Oliva Argüelles B; Fernández Masso JR; Rodríguez-Ulloa A; Cruz García Y; Guirola-Cruz O; Perez-Riverol Y; Javier González L; Tiscornia I; Victoria S; Bollati-Fogolín M; Besada Pérez V; Guerra Vallespi M
    J Proteomics; 2015 Aug; 126():163-71. PubMed ID: 26013411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells.
    Sesarman A; Tefas L; Sylvester B; Licarete E; Rauca V; Luput L; Patras L; Banciu M; Porfire A
    Pharmacol Rep; 2018 Apr; 70(2):331-339. PubMed ID: 29477042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumour peptide based on a protein derived from the horseshoe crab: CIGB-552 a promising candidate for cancer therapy.
    Oliva Arguelles B; Riera-Romo M; Guerra Vallespi M
    Br J Pharmacol; 2020 Aug; 177(16):3625-3634. PubMed ID: 32436254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic Study to Survey the CIGB-552 Antitumor Effect.
    Rodríguez-Ulloa A; Gil J; Ramos Y; Hernández-Álvarez L; Flores L; Oliva B; García D; Sánchez-Puente A; Musacchio-Lasa A; Fernández-de-Cossio J; Padrón G; González López LJ; Besada V; Guerra-Vallespí M
    Biomed Res Int; 2015; 2015():124082. PubMed ID: 26576414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COMMD1 disrupts HIF-1alpha/beta dimerization and inhibits human tumor cell invasion.
    van de Sluis B; Mao X; Zhai Y; Groot AJ; Vermeulen JF; van der Wall E; van Diest PJ; Hofker MH; Wijmenga C; Klomp LW; Cho KR; Fearon ER; Vooijs M; Burstein E
    J Clin Invest; 2010 Jun; 120(6):2119-30. PubMed ID: 20458141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines.
    Vázquez-Blomquist D; Ramón AC; Rosales M; Pérez GV; Rosales A; Palenzuela D; Perera Y; Perea SE
    BMC Genomics; 2023 Jul; 24(1):373. PubMed ID: 37400761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo.
    Farina HG; Benavent Acero F; Perera Y; Rodríguez A; Perea SE; Castro BA; Gomez R; Alonso DF; Gomez DE
    Exp Cell Res; 2011 Jul; 317(12):1677-88. PubMed ID: 21565189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of COMMD1 by miR-205 promotes a positive feedback loop for amplifying inflammatory- and stemness-associated properties of cancer cells.
    Yeh DW; Chen YS; Lai CY; Liu YL; Lu CH; Lo JF; Chen L; Hsu LC; Luo Y; Xiang R; Chuang TH
    Cell Death Differ; 2016 May; 23(5):841-52. PubMed ID: 26586569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of lysine acetyltransferases impairs tumor angiogenesis acting on both endothelial and tumor cells.
    Di Martile M; Gabellini C; Desideri M; Matraxia M; Farini V; Valentini E; Carradori S; Ercolani C; Buglioni S; Secci D; Andreazzoli M; Del Bufalo D; Trisciuoglio D
    J Exp Clin Cancer Res; 2020 Jun; 39(1):103. PubMed ID: 32498717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines.
    Cirigliano SM; Díaz Bessone MI; Berardi DE; Flumian C; Bal de Kier Joffé ED; Perea SE; Farina HG; Todaro LB; Urtreger AJ
    Cancer Cell Int; 2017; 17():42. PubMed ID: 28373828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imperatorin suppresses proliferation and angiogenesis of human colon cancer cell by targeting HIF-1α via the mTOR/p70S6K/4E-BP1 and MAPK pathways.
    Mi C; Ma J; Wang KS; Zuo HX; Wang Z; Li MY; Piao LX; Xu GH; Li X; Quan ZS; Jin X
    J Ethnopharmacol; 2017 May; 203():27-38. PubMed ID: 28341244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.